EDGEWISE THERAPEUTICS INC's ticker is EWTX and the CUSIP is 28036F105. A total of 95 filers reported holding EDGEWISE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $29,225,566 | -8.3% | 1,622,741 | -7.2% | 0.01% | -16.7% |
| Q1 2024 | $31,880,674 | +230.4% | 1,747,844 | +98.2% | 0.01% | +200.0% |
| Q4 2023 | $9,647,943 | +77.7% | 881,896 | -7.0% | 0.00% | +100.0% |
| Q3 2023 | $5,430,860 | -60.0% | 947,794 | -46.0% | 0.00% | -66.7% |
| Q2 2023 | $13,592,330 | +170.2% | 1,753,849 | +132.6% | 0.00% | +200.0% |
| Q1 2023 | $5,030,107 | -47.2% | 754,139 | -29.2% | 0.00% | -50.0% |
| Q4 2022 | $9,522,182 | +1545708.8% | 1,065,121 | +1601.4% | 0.00% | – |
| Q3 2022 | $616 | -46.9% | 62,601 | -57.1% | 0.00% | – |
| Q2 2022 | $1,161 | -99.9% | 145,815 | +10.3% | 0.00% | – |
| Q1 2022 | $1,282,000 | +107.1% | 132,166 | +226.2% | 0.00% | – |
| Q4 2021 | $619,000 | -70.8% | 40,512 | -37.9% | 0.00% | -100.0% |
| Q1 2021 | $2,121,000 | – | 65,263 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,553,661 | $27,981,435 | 34.02% |
| Novo Holdings A/S | 6,344,430 | $114,263,184 | 6.63% |
| Orbimed Advisors | 15,021,721 | $270,541,195 | 5.34% |
| TCG Crossover Management, LLC | 2,272,728 | $40,931,831 | 4.27% |
| Frazier Life Sciences Management, L.P. | 3,731,067 | $67,196,517 | 3.14% |
| Cormorant Asset Management, LP | 3,006,534 | $54,147,677 | 3.13% |
| Opaleye Management Inc. | 580,000 | $10,445,800 | 2.39% |
| RA Capital Management | 8,909,091 | $160,452,729 | 2.12% |
| VR Adviser, LLC | 1,818,182 | $32,745,458 | 2.08% |
| MPM BioImpact LLC | 740,661 | $13,339,305 | 2.07% |